🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Trial S2312 asks if testing for aggressive variant #prostatecancer (AVPC-MS) can help guide treatment. Enrolling patients with #mCRPC previously treated w docetaxel, but no prior cabazitaxel or carboplatin. Biostatistician: Cathy M. Tangen, DrPH Fred Hutch Cancer Center swog.org/clinical-trial…

Site feedback let the team adjust the protocol & complete this $ navig study. Addressing Challenges in Research Aimed at Reducing Financial Toxicity Among Cancer Patients & Caregivers: An Example From the CREDIT Study (SWOG Cancer Research Network S1912CD), via Cancer Control journals.sagepub.com/doi/10.1177/10…

Many people with #cancer are treated with drugs called immune checkpoint inhibitors. #ClinicalTrial S2013 #ICHECKIT may help us predict who is at risk for side effects from these drugs. Learn more: SWOG.org/S2013. Or call 1-800-4-CANCER. Ask about S2013.

#Prostatecancer study S2312 compares usual cabazitaxel treatment to chemo with cabazitaxel and carboplatin. It also uses tumor testing to identify aggressive variant prostate cancer. SWOG.org/S2312. 1-800-4-CANCER. #pcsm

S2013 #ICHECKIT is enrolling again, but at #NCORP sites only. Enrolling patients starting ICI + chemo for #NSCLC, small-cell #lungcancer, #TNBC, or gastroesophageal #cancer. TM chair: Siwen Hu-Lieskovan @HuntsmanCancer swog.org/clinical-trial…

Our #TranslationalMedicine Link of the Week, chosen by SWOG Cancer Research Network's Lee Ellis & Jimmy Rae, PhD (a day early this week, in recognition of the U.S. holiday): Aurora Kinases Signaling in Cancer: From Molecular Perception to Targeted Therapies doi.org/10.1186/s12943…

Our C Blanke, SWOG Chair blog: Happy Independence Day I hope you and your loved ones enjoy whatever celebration, fireworks, picnic, or just simple rest and relaxation you have planned. I know I will! swog.org/news-events/ne…

S2013 #ICHECKIT is reopened and enrolling at #NCORP sites. Developing a risk prediction model for #irAEs from ICI-based therapy. Also exploring the association of dietary fiber intake with severe #irAEs. ECOG-ACRIN Cancer Research Group Champion: Diwakar Davar, M.D. UPMC Hillman Cancer Center swog.org/clinical-trial…

Testing for certain features in cancer (biomarkers) can tell doctors about what’s causing it to grow. The #myeloMATCH study uses advanced biomarker testing for adults with #AML or #MDS. 1-800-4-CANCER or swog.org/myeloMATCH National Cancer Institute Alliance for Clinical Trials in Oncology CCTG ECOG-ACRIN Cancer Research Group

S2312 trial of cabazitaxel w/wo carboplatin in #mCRPC. Starting cabazitaxel dose is 25 mg/m^2, but providers can select 20 mg/m^2 (before randomization) to reflect FDA approval of that lower dose in 2017. Alliance Champion: Mohammad Atiq, M.D. UChicago Medicine swog.org/clinical-trial…

Do you have T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that didn’t get better with treatment — or went away and came back? Ask your doctor about #ClinicalTrial S1905. SWOG.org/S1905. 1-800-4-CANCER. #ALLsm #leusm

On Thursday, July 10th, 10 am ET, the NCI's Center for Global Health hosts a webinar on SWOG Cancer Research Network's Latin America Initiative! Details at: events.cancer.gov/cgh/gcrcss/upc… Register at: events.cancer.gov/cgh/gcrcss/reg…

DART (SWOG Cancer Research Network S1609) rare cancer trial results of dual-ICI therapy in the pancreatic neuroendocrine neoplasm (PNEN) cohort, just published in Journal for ImmunoTherapy of Cancer: Clinical benefit rate (incl stable disease >6 mo + objective response) of 26%, w durable benefit >2 yrs in 3 of 19 patients.

Phase 3 SWOG Cancer Research Network S2312 randomizes patients with metastatic castrate-resistant #ProstateCancer to cabazitaxel w or w/out carboplatin. All are screened for an aggressive variant signature (AVPC-MS), used to stratify. Co-PIs: Ana Aparicio & David VanderWeele MD PhD swog.org/clinical-trial…

Lung-MAP 3.0’s easier genetic screening process means Lung-MAP will be even better positioned to enroll a group of patients fully representative of the population of patients with advanced #NSCLC in the U.S. lung-map.org Foundation for the National Institutes of Health Friends of Cancer Research SWOG Cancer Research Network National Cancer Institute

Our #TranslationalMedicine Link of the Week, chosen by SWOG Cancer Research Network's Lee Ellis & Jimmy Rae, PhD: ESMO-ESTRO Framework for Assessing the Interactions and Safety of Combining Radiotherapy with Targeted Cancer Therapies or Immunotherapy doi.org/10.1016/j.rado…

Our C Blanke, SWOG Chair's blog: It’s Hard to Believe, but Coming Next Tuesday: Fall Meeting Registration On July 15th, online registration opens for the SWOG Cancer Research Network fall 2025 group meeting in Chicago, September 18th - 20th. Plan now to be there then. swog.org/news-events/ne…

A phase 1/2 trial in #mCRPC found adding carboplatin to cabazitaxel improved PFS & OS in patients whose tumors had an AVPC-MS aggressive variant signature. SWOG Cancer Research Network S2312 puts this to a phase 3 test. TM chairs: David McConkey & Amir Goldkorn, MD swog.org/clinical-trial…

The SWOG Cancer Research Network S1501 trial has reopened and is enrolling patients w HER2+ #breastcancer to its observation-only arm (Arm 3). Arms 1 & 2 are closed, but patients already on these arms continue protocol-specified therapy. PI: Justin Floyd, DO, CCSI swog.org/clinical-trial…

Our #TranslationalMedicine Link of the Week, chosen by SWOG Cancer Research Network's Lee Ellis & Jimmy Rae, PhD: Prevalence of Symptomatic Toxicities for Novel Therapies in Adult Oncology Trials: A Scoping Review doi.org/10.1093/jncics…